OBJECTIVE: Dysadherin is a cancer-associated cell membrane glycoprotein that has been reported to downregulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in metastasis of esophageal squamous cell carcinoma (ESCC), we examined dysadherin and E-cadherin expression in patients with this cancer. METHODS: Dysadherin and E-cadherin expression was evaluated in 117 ESCC patients (pT1, 31; pT2, 30; pT3, 39; pT4, 17) by immunohistochemistry. The findings were compared with the clinicopathological data of the patients. RESULTS: Both dysadherin and E-cadherin were localized to the cell membrane. Thirty patients (29.1%) had tumors positive for dysadherin and 41 patients (35.0%) had tumors positive for E-cadherin. Tumors showing dysadherin positivity and negative E-cadherin expression had a significantly worse prognosis than other tumors. When the patients with dysadherin- positive tumors were combined with E-cadherin-negative patients, this group had a worse prognosis (p < 0.0001). Cox multivariate analysis revealed that dysadherin expression was an independent prognostic factor for ESCC (p = 0.003), but E-cadherin expression was not. CONCLUSION: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis of patients with ESCC. Our results suggested that expression of dysadherin by this cancer may partly explain the poor prognosis of patients with preservation of E-cadherin expression. Copyright 2004 S. Karger AG, Basel
OBJECTIVE:Dysadherin is a cancer-associated cell membrane glycoprotein that has been reported to downregulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in metastasis of esophageal squamous cell carcinoma (ESCC), we examined dysadherin and E-cadherin expression in patients with this cancer. METHODS:Dysadherin and E-cadherin expression was evaluated in 117 ESCC patients (pT1, 31; pT2, 30; pT3, 39; pT4, 17) by immunohistochemistry. The findings were compared with the clinicopathological data of the patients. RESULTS: Both dysadherin and E-cadherin were localized to the cell membrane. Thirty patients (29.1%) had tumors positive for dysadherin and 41 patients (35.0%) had tumors positive for E-cadherin. Tumors showing dysadherin positivity and negative E-cadherin expression had a significantly worse prognosis than other tumors. When the patients with dysadherin- positive tumors were combined with E-cadherin-negative patients, this group had a worse prognosis (p < 0.0001). Cox multivariate analysis revealed that dysadherin expression was an independent prognostic factor for ESCC (p = 0.003), but E-cadherin expression was not. CONCLUSION: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis of patients with ESCC. Our results suggested that expression of dysadherin by this cancer may partly explain the poor prognosis of patients with preservation of E-cadherin expression. Copyright 2004 S. Karger AG, Basel
Authors: Catharina Steentoft; Max Fuhrmann; Federico Battisti; Julie Van Coillie; Thomas D Madsen; Diana Campos; Adnan Halim; Sergey Y Vakhrushev; Hiren J Joshi; Hans Schreiber; Ulla Mandel; Yoshiki Narimatsu Journal: Glycobiology Date: 2019-04-01 Impact factor: 4.313
Authors: K Juurikka; A Dufour; K Pehkonen; B Mainoli; P Campioni Rodrigues; N Solis; T Klein; P Nyberg; C M Overall; T Salo; P Åström Journal: Oncogenesis Date: 2021-05-31 Impact factor: 7.485
Authors: A Batistatou; C D Scopa; P Ravazoula; Y Nakanishi; D Peschos; N J Agnantis; S Hirohashi; K A Charalabopoulos Journal: Br J Cancer Date: 2005-12-12 Impact factor: 7.640
Authors: A Batistatou; D Peschos; H Tsanou; A Charalabopoulos; Y Nakanishi; S Hirohashi; N J Agnantis; K Charalabopoulos Journal: Br J Cancer Date: 2007-04-17 Impact factor: 7.640